“AF1q has a precise oncogenic function.
The purpose of this study is to investigate whether CBD has an effect on the AF1q/ICAM-1 regulatory axis in Burkitt’s lymphoma (BL), and thus has potential to enhance immunotherapy and reduce side effects.
RESULTS:
AF1q increased oncogenic growth and colony formation, and induced resistance against cell-mediated cytotoxic chemotherapy through attenuation of ICAM-1 expression in BL. CBD was able to reverse the acquired resistance mediated by AF1q/ICAM-1 regulatory axis.
CONCLUSION:
CBD holds potential to enhance the efficacy of immunotherapy for BL with hyperactive AF1q/ICAM-1 regulatory axis, and warrants further study.”
https://www.ncbi.nlm.nih.gov/pubmed/31587870
“Non-psychoactive CBD could potentially enhance the efficacy of immunotherapy in cancer treatment, especially against aggressive B.”
https://www.sciencedirect.com/science/article/pii/S0006291X1931890X?via%3Dihub
